Short answer
Benitec Biopharma Inc. (BNTC) filed an 8-K current report with the SEC on May 29, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). David Friedman appointed Class III director through 2028 annual meeting.
Benitec Biopharma Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- David Friedman appointed Class III director through 2028 annual meeting
- 35,000 stock options granted at May 26 closing price, vesting by next annual meeting or first anniversary
- Megan Boston resigned from the Board while retaining CFO and secretary roles
- Board transition described as governance review, with no operational or policy disagreement disclosed
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Benitec Biopharma Inc. 8-K filings
Get the next BNTC 8-K as it lands
Follow BNTC for push alerts, or ask the research agent what this filing means.